Don’t miss the latest developments in business and finance.

Vivimed Labs gains on zero 483 observations from USFDA

The stock rallied 7% to Rs 112 on BSE in early morning trade.

pharma, pharma industry
Govt proposes to bring fixed-dose combinations under price control
SI Reporter Mumbai
Last Updated : Jun 07 2017 | 9:36 AM IST
Vivimed Labs  rallied 7% to Rs 112 on the BSE in early morning trade after the US health regulator recently inspected the company’s manufacturing plant in Spain and did not issue any observations.

The company’s active pharmaceutical ingredient (API) manufacturing facility located at Sant Celoni, Spain, was recently inspected by the United States Food and Drug Administration (USFDA).

At the end of the successful inspection, ‘zero’ 483 observations were issued. This was a routine inspection by the USFDA, Vivimed Labs said in a release.

At 09:28 am; the stock was up 6% at Rs 111.65 on BSE as compared to 0.24% rise in the S&P BSE Sensex. A combined 782,310 shares changed hands on the counter on BSE and NSE so far.

Next Story